Aigen Investment Management LP Purchases New Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Aigen Investment Management LP acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,785 shares of the company’s stock, valued at approximately $345,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Meritage Portfolio Management grew its holdings in Prestige Consumer Healthcare by 11.0% in the third quarter. Meritage Portfolio Management now owns 11,992 shares of the company’s stock worth $865,000 after purchasing an additional 1,193 shares during the period. Covestor Ltd grew its holdings in Prestige Consumer Healthcare by 95.6% in the third quarter. Covestor Ltd now owns 1,338 shares of the company’s stock worth $96,000 after purchasing an additional 654 shares during the period. Portside Wealth Group LLC grew its holdings in Prestige Consumer Healthcare by 12.4% in the third quarter. Portside Wealth Group LLC now owns 6,389 shares of the company’s stock worth $461,000 after purchasing an additional 707 shares during the period. US Bancorp DE grew its holdings in Prestige Consumer Healthcare by 20.3% in the third quarter. US Bancorp DE now owns 3,978 shares of the company’s stock worth $287,000 after purchasing an additional 672 shares during the period. Finally, Congress Asset Management Co. grew its holdings in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after purchasing an additional 62,411 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.5 %

Shares of NYSE PBH opened at $82.36 on Friday. The company has a market cap of $4.07 billion, a PE ratio of 20.04, a P/E/G ratio of 2.32 and a beta of 0.47. The firm’s 50 day moving average price is $73.13 and its 200-day moving average price is $70.18. Prestige Consumer Healthcare Inc. has a 52-week low of $56.61 and a 52-week high of $83.83. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same quarter in the prior year, the firm earned $1.07 earnings per share. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,935 shares of company stock valued at $2,289,025 over the last three months. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

PBH has been the topic of several analyst reports. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.